Готові списки джерел за темами / 006.350 72

Зміст

Статті в журналах
Частини книг
Тези доповідей конференцій

Добірка наукової літератури з теми "006.350 72"

Автор: Grafiati

Опубліковано: 1 березня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "006.350 72".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "006.350 72"

Tsimberidou, A. M., C. Tam, W. Wierda, S. O' Brien, S. Lerner, and M. J. Keating. "Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl)." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 7034. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7034.

Повний текст джерела

Анотація:

7034 Introduction: High β2M levels are a risk factor in CLL. PCR therapy has been reported to be better tolerated than FCR in older or with decrease renal function pts (Shanafelt, Blood 108:15a). We assessed the association between age, CrCl, PS, β2M and outcomes in pts treated with FCR. Methods: From 7/99 to 1/04, 300 pts received rituximab 375 mg/m2 D1; fludarabine 25 mg/m2/d D2–3; and cyclophosphamide 250 mg/m2/d D2–3. Serum β2M levels were measured by radioimmunoassay. CrCl was calculated (Cockcroft-Gault equation). Results: The median age was 57 yrs (≥70, 14%). Age ≥70 was associated with fewer FCR courses (p<.0001); lower rates of CR (p=.001), overall response (OR; p=.04), survival (OS; p<.0001), and FFS (p=.008); and higher rates of G3–4 thrombopenia (p<.0001) or anemia (p=.002) compared with age<70. The median CrCl was 90 mL/min (CrCl <70, 27%). Pts with CrCl <70 had higher rates of G3–4 thrombopenia (p=.006) or anemia (p=.01) than others. There were no differences between the 2 groups in the other outcomes. PS was 0 in 40%, 1 in 57%, and 2 in 3% of pts. Better PS was associated with higher rates of CR (p=.007) and FFS (p=.02) but did not affect OR or OS. The median β2M level was 3.7 mg/L (β2M ≥ 4, 43%). The rates of CR, survival, and FFS were lower in pts with β2M ≥ 4 compared with others (p<.0001 each). High β2M levels were associated with older age, lower CrCl levels, poorer PS (p<.0001 each), higher rates of G3–4 neutropenia (p=.005), thrombocytopenia (p=.01), and infections (p=.03), and fewer FCR courses (p=.004). The median follow-up was 5 yrs. The rates of CR, 3-yr OS and 3-yr FFS were 72%, 87% and 76%, respectively. Independent factors predicting response were lower β2M (p=.0004) and lower WBC counts (p=.02). Independent factors predicting longer OS were younger age (p=.001), lower β2M (p=.003) and lower WBC (p=.03). Independent factors predicting longer FFS were lower β2M levels (p=.0006), and lower WBC counts (p=.005). Conclusion: Age ≥70 yrs and poor PS, but not CrCl level were associated with poor clinical outcomes. High β2M levels are an independent adverse prognostic factor for CR, OS, and FFS in the context of other prognostic factors. No significant financial relationships to disclose.

Стилі APA, Harvard, Vancouver, ISO та ін.

Yuan, Ying, Hong Qiu, Lei Song, Xiaoying Hu, Tong Luo, Xueyan Zhao, Jun Zhang, et al. "A New Risk Factor Profile for Contrast-Induced Acute Kidney Injury in Patients Who Underwent an Emergency Percutaneous Coronary Intervention." Angiology 69, no. 6 (October 29, 2017): 523–31. http://dx.doi.org/10.1177/0003319717736157.

Повний текст джерела

Анотація:

We developed a new risk factor profile for contrast-induced acute kidney injury (CI-AKI) under a new definition in patients who underwent an emergency percutaneous coronary intervention (PCI). Consecutive patients (n = 1061) who underwent an emergency PCI were divided into a derivation group (n = 761) and a validation group (n = 300). The rates of CI-AKI were 23.5% (definition 1: serum creatinine [SCr] increase ≥25% in 72 hours), 4.3% (definition 2: SCr increase ≥44.2 μmol/L in 72 hours), and 7.0% (definition 3: SCr increase ≥44.2 μmol/L in 7 days). Due to the high sensitivity of definition 1 and the high rate of missed cases for late diagnosis of CI-AKI under definition 2, definition 3 was used in the study. The risk factor profile included body surface area <1.6 m2 ( P = .030), transient ischemic attack/stroke history ( P = .001), white blood cell count >15.00 × 109/L ( P = .047), estimated glomerular filtration rate <60 mL/min/1.73 m2 ( P = .002) or baseline SCr >133 μmol/L ( P = .007), intra-aortic balloon pump application ( P = .006), and diuretics administration ( P < .001), showing a significant predictive power in the derivation group and validation group. The new risk factor profile of CI-AKI under a new CI-AKI definition in emergency PCI patients is easily applicable with a useful predictive value.

Стилі APA, Harvard, Vancouver, ISO та ін.

Daneshfar, Amin, Carl J. Petersen, Majid S. Koozehchian, and Daniel E. Gahreman. "Caffeinated Chewing Gum Improves Bicycle Motocross Time-Trial Performance." International Journal of Sport Nutrition and Exercise Metabolism 30, no. 6 (November 1, 2020): 427–34. http://dx.doi.org/10.1123/ijsnem.2020-0126.

Повний текст джерела

Анотація:

This study aimed to identify the acute effects of caffeinated chewing gum (CAF) on bicycle motocross (BMX) time-trial (TT) performance. In a randomized, placebo-controlled, double-blind cross-over design, 14 male BMX riders (age = 20.0 ± 3.3 years; height = 1.78 ± 0.04 m; body mass = 72 ± 4 kg), consumed either (300 mg; 4.2 ± 0.2 mg/kg) caffeinated (300 mg caffeine, 6 g sugars) or a placebo (0 mg caffeine, 0 g sugars) gum, and undertook three BMX TTs. Repeated-measure analysis revealed that CAF has a large ergogenic effect on TT time, F(1, 14) = 33.570, p = .001, ; −1.5% ± 0.4 compared with the placebo. Peak power and maximal power to weight ratio also increased significantly compared with the placebo condition, F(1, 14) = 54.666, p = .001, ; +3.5% ± 0.6, and F(1, 14) = 57.399, p = .001, ; +3% ± 0.3, respectively. Rating of perceived exertion was significantly lower F(1, 14) = 25.020, p = .001, in CAF (6.6 ± 1.3) compared with the placebo (7.2 ± 1.7). Administering a moderate dose (300 mg) of CAF could improve TT time by enhancing power and reducing the perception of exertion. BMX coaches and riders may consider consuming CAF before a BMX race to improve performance and reduce rating of perceived exertion.

Стилі APA, Harvard, Vancouver, ISO та ін.

Fishman, Loren M. "Isometric Yoga-Like Maneuvers Improve Adolescent Idiopathic Scoliosis—A Nonrandomized Control Trial." Global Advances in Health and Medicine 10 (January 2021): 216495612098825. http://dx.doi.org/10.1177/2164956120988259.

Повний текст джерела

Анотація:

Objective Assess therapeutic value of specific yoga poses for thoracic and lumbar adolescent idiopathic scoliosis (AIS) taught in office or Internet. Study Design Nonrandomized control trial: Fifty-six adolescents (mean age 14.0 years; mean Risser 3.0) were recruited from our clinic; 41 did the side-plank, the half-moon and elevated side plank poses as appropriate (treatment group) and 15 did not (controls). Thirty curves were treated in office, 30 via Internet. Curve change was evaluated by blinded serial Cobb angles, and analyzed using Mann-Whitney U, paired t-tests and χ2. Results Mean lumbar and thoracolumbar Cobb angle change was −9.2 (95% CI = −11.8, −6.6) in the treatment group and 5.4 (95% CI = 1.7, 9.0) in controls. Both treatment group improvement and deterioration in controls were significant (treatment group: paired t-test t = −7.1, df = 40, p = .000; controls: t = 3.2, df = 12, p = .008). Mean thoracic Cobb angle change was −7.1 (95% CI = −13.1, −1.2) in the treatment group and 9.3 (95% CI = 4.5, 14.6) in controls. Both changes were significant (paired t-test t = −3.3, df = 21, p = .022 for treatment group; t = 4.5, df = 5, p = .006 for controls). Nine Internet patients were non-compliant vs. 6 office patients. Office patients improved 1.6 degrees/month or 5.5%/month; Internet patients improved .72 degrees/month or 3.3%/month. Conclusion These yoga poses show promise for reversing adolescent idiopathic scoliosis. Telemedicine had greater non-compliance and lower efficacy but still produced patient improvement.

Стилі APA, Harvard, Vancouver, ISO та ін.

Hofheimer, Julie A., Monica McGrath, Rashelle Musci, Guojing Wu, Sarah Polk, Courtney K. Blackwell, Annemarie Stroustrup, et al. "Assessment of Psychosocial and Neonatal Risk Factors for Trajectories of Behavioral Dysregulation Among Young Children From 18 to 72 Months of Age." JAMA Network Open 6, no. 4 (April 26, 2023): e2310059. http://dx.doi.org/10.1001/jamanetworkopen.2023.10059.

Повний текст джерела

Анотація:

ImportanceEmotional and behavioral dysregulation during early childhood are associated with severe psychiatric, behavioral, and cognitive disorders through adulthood. Identifying the earliest antecedents of persisting emotional and behavioral dysregulation can inform risk detection practices and targeted interventions to promote adaptive developmental trajectories among at-risk children.ObjectiveTo characterize children’s emotional and behavioral regulation trajectories and examine risk factors associated with persisting dysregulation across early childhood.Design, Setting, and ParticipantsThis cohort study examined data from 20 United States cohorts participating in Environmental influences on Child Health Outcomes, which included 3934 mother-child pairs (singleton births) from 1990 to 2019. Statistical analysis was performed from January to August 2022.ExposuresStandardized self-reports and medical data ascertained maternal, child, and environmental characteristics, including prenatal substance exposures, preterm birth, and multiple psychosocial adversities.Main Outcomes and MeasuresChild Behavior Checklist caregiver reports at 18 to 72 months of age, with Dysregulation Profile (CBCL-DP = sum of anxiety/depression, attention, and aggression).ResultsThe sample included 3934 mother-child pairs studied at 18 to 72 months. Among the mothers, 718 (18.7%) were Hispanic, 275 (7.2%) were non-Hispanic Asian, 1220 (31.8%) were non-Hispanic Black, 1412 (36.9%) were non-Hispanic White; 3501 (89.7%) were at least 21 years of age at delivery. Among the children, 2093 (53.2%) were male, 1178 of 2143 with Psychosocial Adversity Index [PAI] data (55.0%) experienced multiple psychosocial adversities, 1148 (29.2%) were exposed prenatally to at least 1 psychoactive substance, and 3066 (80.2%) were term-born (≥37 weeks’ gestation). Growth mixture modeling characterized a 3-class CBCL-DP trajectory model: high and increasing (2.3% [n = 89]), borderline and stable (12.3% [n = 479]), and low and decreasing (85.6% [n = 3366]). Children in high and borderline dysregulation trajectories had more prevalent maternal psychological challenges (29.4%-50.0%). Multinomial logistic regression analyses indicated that children born preterm were more likely to be in the high dysregulation trajectory (adjusted odds ratio [aOR], 2.76; 95% CI, 2.08-3.65; P &lt; .001) or borderline dysregulation trajectory (aOR, 1.36; 95% CI, 1.06-1.76; P = .02) vs low dysregulation trajectory. High vs low dysregulation trajectories were less prevalent for girls compared with boys (aOR, 0.60; 95% CI, 0.36-1.01; P = .05) and children with lower PAI (aOR, 1.94; 95% CI, 1.51-2.49; P &lt; .001). Combined increases in PAI and prenatal substance exposures were associated with increased odds of high vs borderline dysregulation (aOR, 1.28; 95% CI, 1.08-1.53; P = .006) and decreased odds of low vs high dysregulation (aOR, 0.77; 95% CI, 0.64-0.92; P = .005).Conclusions and RelevanceIn this cohort study of behavioral dysregulation trajectories, associations were found with early risk factors. These findings may inform screening and diagnostic practices for addressing observed precursors of persisting dysregulation as they emerge among at-risk children.

Стилі APA, Harvard, Vancouver, ISO та ін.

Reddy, Akhila Sunkepally, Maxine Grace Jaucian De La Cruz, Eden Mae Rodriguez, Jessica Thames, Jimin Wu, Gary B. Chisholm, Diane Liu, et al. "Storage, disposal, and utilization of opioids among cancer outpatients." Journal of Clinical Oncology 31, no. 31_suppl (November 1, 2013): 222. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.222.

Повний текст джерела

Анотація:

222 Background: Prescription opioid abuse is an epidemic in the US. Of the abusers, 75% obtain the opioid from a friend or relative, which may be related to improper opioid storage and disposal practices. Our aim was to determine patients’ practices of opioid use, storage, and disposal. Methods: We surveyed 300 cancer outpatients presenting to our Supportive Care Center who were receiving opioids for at least 1 month and collected information regarding opioid use, storage, and disposal along with patient characteristics and scores on Cut-down, Annoyed, Guilty, Eye-opener (CAGE) questionnaire for alcoholism. Sharing or losing their opioids was defined as an unsafe use. Results: The median age of the patients was 57 years; 53% were female, 72% were white, and 63% were married. Most (89%) had advanced cancer, and lung cancer was the most common (22%). CAGE was positive in 19%, 9% had history of illicit drug use, and 36% lived with adult/young adult children. Of the 300 respondents, 19% stored opioids in the open, 69% kept opioids hidden but unlocked, and 9% locked their opioids. Patients with history of CAGE positivity (P=.007), illicit drug use (.0002), smoking (P=.03), and those living with adult children (P=.004) were more likely to keep their opioids locked. 66% were unaware of proper opioid disposal methods. 46% had unused opioids at home. 53% did not routinely dispose opioids, of whom 44% saved them for future use. 26% indulged in unsafe use by sharing (9%) or losing (17%) their opioids, and 44% informed their family and friends that they were on pain medications. 39% were unaware that their opioid could be fatal when taken by others. Compared with married patients, those who were never married [OR=2.92; 95% CI 1.48-5.77], separated [OR=11.38; 1.52-112.5], or divorced [OR=1.27; 0.55-2.91] had higher odds of unsafe use (P=.006). CAGE positivity (40% vs. 21%, P=.003) and illicit drug use (42% vs. 23%, P=.031) were also significant predictors of unsafe use. Conclusions: An alarming proportion of patients improperly and unsafely use, store, and dispose of opioids. Patient education by physicians/pharmacists and creation of more drug take back programs may reduce availability of prescription opioids for potential abuse. More research is needed in this area.

Стилі APA, Harvard, Vancouver, ISO та ін.

LIU, Q., C. WANG, G. GUO, W. Z. YANG, K. H. DONG, Y. X. HUANG, X. M. YANG, and D. C. HE. "Effects of calcium propionate on rumen fermentation, urinary excretion of purine derivatives and feed digestibility in steers." Journal of Agricultural Science 147, no. 2 (January 23, 2009): 201–9. http://dx.doi.org/10.1017/s0021859609008429.

Повний текст джерела

Анотація:

SUMMARYThe objective of the current study was to evaluate the effects of calcium propionate supplementation on rumen fermentation, urinary excretion of purine derivatives (PD) and feed digestibility in the total gastrointestinal tract of steers. Eight ruminally cannulated Simmental steers (462±14 kg) were used in a replicated 4×4 Latin square arrangement of treatments with experimental periods of 21 days. The treatments were: control (without calcium propionate), LCaP (calcium propionate – low), MCaP (calcium propionate – medium) and HCaP (calcium propionate – high) with 100, 200 and 300 g calcium propionate per steer per day. Diet consisted of 0·60 maize stover and 0·40 concentrate (dry matter (DM) basis). DM intake (average 9 kg/day) was restricted to a maximum of 0·90 ofad libitumintake. Ruminal pH (range of 6·7–6·5) linearly (P<0·003) and quadratically (P<0·005) decreased, and total volatile fatty acid (VFA) concentration (range of 64·4–67·1 mm) tended (P<0·087) to increase linearly with rising calcium propionate supplementation. Ratio of acetate to propionate fell linearly (P<0·006) and quadratically (P<0·008) from 3·5 to 2·6 as calcium propionate supplementation increased due to the additional propionate supplementation.In situruminal neutral detergent fibre (NDF) degradation of maize stover and crude protein (CP) degradability of concentrate mix were improved with increasing concentration of calcium propionate. Urinary excretion of PD was linearly (P<0·032) and quadratically (P<0·048) increased with greater calcium propionate supplementation (72, 74, 77 and 76 mmol/day for control, LCaP, MCaP and HCaP, respectively). Similarly, digestibilities of organic matter (OM), NDF and CP in the total tract were also linearly and quadratically improved with increasing calcium propionate. The results indicate that the calcium propionate supplementation potentially improves rumen fermentation and feed digestion in beef cattle. It is speculated that calcium propionate stimulates the digestive microorganisms or enzymes in a dose-dependent manner. In the experimental conditions of the current trial, the optimum calcium propionate dose was about 200 g calcium propionate per steer per day.

Стилі APA, Harvard, Vancouver, ISO та ін.

Siegel, David S., Jesus G. Berdeja, Jeffrey R. Infante, Jonathan L. Kaufman, Michael (Luhua) Wang, Thomas G. Martin, Ruben Niesvizky, et al. "Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)." Blood 124, no. 21 (December 6, 2014): 2134. http://dx.doi.org/10.1182/blood.v124.21.2134.2134.

Повний текст джерела

Анотація:

Abstract Introduction: PX-171-010 (010; NCT00884312) is an extension study of patients who completed a phase 1 or 2 carfilzomib study that aims to provide insights into the long-term tolerability, safety, and clinical benefit of carfilzomib. Methods: Patients who completed a carfilzomib study were eligible to enroll and continue receiving carfilzomib at the same dosing level, with dose adjustments permitted per protocol. Addition of other approved anticancer agents at the time of progression was allowed. The primary end point was safety; efficacy was also evaluated. Results: Between 2009 and 2012, patients with multiple myeloma (MM; n=91) or solid tumors (ST; n=9) were enrolled in this extension study. Patients were enrolled from the PX-171-002, PX-171-003-A0, PX-171-003-A1, PX-171-004, PX-171-005, PX-171-006, PX-171-007, and PX-171-008 studies (Table 1). Among patients with MM, 57.1% had prior bortezomib exposure and 95.6% had prior immunomodulatory agent (IMiD) exposure; 37.4% were refractory to bortezomib, 61.5% were refractory to an IMiD, and 31.9% were refractory to both bortezomib and an IMiD. In the initial studies, patients received 15–70 mg/m2 carfilzomib. In 010, patients received a median dose of 27 mg/m2 carfilzomib (range, 13–52 mg/m2). Median duration of carfilzomib treatment (initial study+010) was 88.9 weeks (range, 4.4–273.4 weeks). Median number of carfilzomib treatment cycles was 22.5 (range, 2–67); 60.0% of patients received carfilzomib for ≥19 cycles and 27.0% for ≥37 cycles. Treatment-emergent grade ≥3 adverse events (AEs) and serious AEs are presented in Table 2. Twenty-three patients (23.0%) had treatment-emergent AEs that led to discontinuation of study treatment, including 18 patients with MM (19.8%). Eight patients (8.0%) died on the 010 study or within 30 days of last dose of study drug, including 7 patients with MM (4 deaths due to AEs, 3 due to disease progression). One patient with ST died due to disease progression. The 4 AE deaths were due to myocardial infarction (MI; n=2), pneumonia (n=1), and pneumonia with MI (n=1). The 3 patients with MI had pre-existing cardiac disease and died after 9–47 cycles on study. None of the 8 deaths were assessed as carfilzomib-related. Overall, 74 patients (74.0%) had ≥1 regimen change. Among patients with MM, 72 patients (79.1%) had ≥1 regimen change; 22 (30.6%) of these patients continued receiving single-agent carfilzomib at a different dose/schedule, and 50 (69.4%) received additional combination therapy, including 48 patients (66.7%) who received dexamethasone, 26 (36.1%) who received lenalidomide, and 25 (34.7%) who received cyclophosphamide. Notably, responses were observed among patients with MM after regimen change due to disease progression: the overall response rate was 20.0% after first progression, 35.0% after second progression, and 30.8% after third progression. Conclusion: The types and rates of AEs in 010 were similar to those previously reported with single-agent carfilzomib. Patients were able to receive carfilzomib for an average of 89 weeks (up to 273 weeks; median of 22.5 treatment cycles) and continued receiving clinical benefit, with no new significant safety signals noted from additional cumulative exposure. Table 1 Patient Enrollment in PX-171-010 by Initial Study Table 1. Patient Enrollment in PX-171-010 by Initial Study Table 2 Treatment-Emergent Grade ≥3 or Serious AEs Occurring in ≥5% of Patients in PX-171-010 Table 2. Treatment-Emergent Grade ≥3 or Serious AEs Occurring in ≥5% of Patients in PX-171-010 Disclosures Off Label Use: Carfilzomib as treatment in multiple myeloma and solid tumors. Kaufman:Millennium: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Onyx: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Spectrum: Consultancy, Honoraria; Merck: Research Funding. Wang:Onyx: Honoraria, Research Funding. Martin:Sanofi: Research Funding; Novartis: Speakers Bureau. Niesvizky:Celgene: Consultancy, Research Funding, Speakers Bureau; Millennium: Consultancy, Research Funding, Speakers Bureau; Onyx: Consultancy, Research Funding, Speakers Bureau. Reu:Onyx: Consultancy, Speakers Bureau. Jagannath:Millennium: Honoraria; Celgene: Honoraria; Onyx: Honoraria; Merck: Honoraria; Ortho Biotech: Membership on an entity's Board of Directors or advisory committees; Imedex: Membership on an entity's Board of Directors or advisory committees; Medicom Worldwide: Membership on an entity's Board of Directors or advisory committees; Optum Health Worldwide: Membership on an entity's Board of Directors or advisory committees; PER group: Membership on an entity's Board of Directors or advisory committees. Rajangam:Onyx Pharmaceuticals, an Amgen subsidiary: Employment, Equity Ownership. Huang:Onyx Pharmaceuticals: Employment. Vij:Celgene: Honoraria, Research Funding; Onyx: Honoraria, Research Funding; Sanofi: Honoraria; Jannsen: Honoraria; Novartis: Honoraria; Millennium: Honoraria; Array: Honoraria.

Стилі APA, Harvard, Vancouver, ISO та ін.

Briantio, Alfred, Sobron Yamin Lubis, and Steven Darmawan. "ANALISIS PENINGKATAN TERJADINYA KEAUSAN MATA PAHAT KERAMIK PADA PROSES PEMOTONGAN BAJA AISI 4340." Jurnal Serina Sains, Teknik dan Kedokteran 2, no. 1 (March 1, 2024): 15–26. http://dx.doi.org/10.24912/jsstk.v2i1.31648.

Повний текст джерела

Анотація:

Proses pemotongan logam tidak dapat dipisahkan dengan penggunaan mata pahat potong. Sifat-sifat mata pahat potong memberi spesifikasi tersendiri terhadap parameter pemotongan. Pertimbangan utama yang dilakukan dalam pemilihan mata pahat potong bergantung pada jenis benda kerja yang digunakan dan proses pemotongan yang dilaksanakan. Berkembangnya bahan benda kerja terutama dalam menghasilkan sifat sifat yang memiliki ketahanan tinggi terhadap kekerasan dan juga suhu pemotongan hal tersebut memicu perkembangan jenis bahan mata pahat potong tersebut. Salah satu jenis mata pahat yang memiliki kekerasan dan ketahanan terhadap temperatur tinggi adalah keramik. Namun demikian, jika digunakan secara kontinu mata pahat akan mengalami keausan. Penelitian ini dilaksanakan bertujuan untuk mengetahui peningkatan terjadinya keausan pada mata pahat keramik ketika melakukan pemotongan baja paduan yang keras seperti AISI 4340. Percobaan dilakukan dengan menggunakan mesin bubut konvensional. jenis mata pahat digunakan dalam penelitian ini yaitu mata pahat keramik type TNGA 160404T02025. Parameter pemotonagan terdiri Kecepatan pemotongan : 140 m/min, 220 m/min, 350 m/min, Putaran spindel : 350 r/min, 710, r/min, 1120 r/min, Kedalaman pemotongan : 0.06 mm, 0.08 mm, 1.00 mm, Hantaran pemotongan : 0.2 mm. Proses pembubutan dilakukan dengan rentang waktu 3menit, maka setiap rentang waktu tersebut pembubutan dihentikan dan dilakukan pengamatan dan pengukuran keausan pada mata pahat. Mata pahat dianggap aus jika telah mencapai nilai 0.3 mm. Dari hasil penelitian diperoleh bahwa kecepatan potong (Vc) berpengaruh terhadap waktu penggunaan mata pahat sisipan. Semakin tinggi kecepatan potong (Vc) maka semakin rendah nilai waktu penggunaan mata pahat sisipan. Nilai keausan mata pahat tercepat yaitu pada menit ke-9 dengan kecepatan potong 350 m/min serta kedalaman potong 0,1 mm dan nilai keausan mata pahat terlama pada menit ke-72 pada kecepatan potong 140 m/menit dan kedalaman potong 0,06 mm.

Стилі APA, Harvard, Vancouver, ISO та ін.

Garifullin, Andrey, Sergei Voloshin, Sergey Linnikov, Irina Martynkevich, Alexey Kuvshinov, Anastasiya Kuzyaeva, Zhanna Chubukina, et al. "The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0." Blood 136, Supplement 1 (November 5, 2020): 42. http://dx.doi.org/10.1182/blood-2020-139239.

Повний текст джерела

Анотація:

Assessment of the role of genetic abnormalities and minimal residual disease (MRD) is an active developing area in hematology. The use of genetic methods makes it possible to predict the course of the disease and apply an individualized approach to antimyeloma therapy. At the same time, the identification of MRD after therapy determines possibility of relapse. Aim. To identify the prognostic potential of MRD in patients in the standard and high molecular risk groups. Materials and methods. We analyzed 72 patients with MM (median age was 59 years (range 37-80), male/female - 1.3:1). All patients received initial therapy with proteasome inhibitors and / or immunomodulators. High dose therapy (MEL200) and autologous stem cell transplantation (ASCT) was carried out 50 (69%) patients. Standard cytogenetic and FISH methods were used to stratify patients in risk groups of mSMART 3.0. The standard risk (SR) was established in 52 (72%) patients, the high risk (HR) - in 20 (28%) patients. The MFC MRD status of bone marrow was evaluated after 4-6 cycles of induction therapy or after ASCT with use of 5-colors flow cytometry. MRD-negative status (MRD-) was based on level of clonal plasma cells <10-4 in bone marrow sample. Results. The MRD- was reached in 36% (26/72) patients. The median of OS in MRD+ group was 104 months, in MRD- was 146 months (p=.01). The median of PFS in MRD+ group was 26 months, in MRD- was 70 months (p=.00021). 2-years PFS in MRD+ group was 56%, in MRD- group was 100% (p=.00021). We divided patients into the following groups for evaluation the effect of MRD on survival in risk groups: SR МRD+ 34/72 (47%), SR МRD- 18/72 (25%), HR МRD+ 12/72 (17%) and HR MFC МRD- 8/72 (11%). The median of OS in HR MRD+ group was 72 months, in SR MRD+ - 104 months, in HR MRD- - 146 months, in SR MRD- was not achieved (p=.02). The median of PFS in HR MRD+ group was 24 months, in SR MRD+ - 26 months, in HR MRD- - 68 months, in SR MRD- - 70 months (p=.003). The 2-years PFS in HR MRD+ group was 44%, in SR MRD+ group was 50% and in SR MRD- and HR MRD- groups were 100% (p=.003). Conclusion. The absence of MRD is the most important prognostic factor. The leveling of negative effect of genetic abnormalities become possible when the MRD-negative response status is achieved. Presumably, this is due to the elimination of clonal plasma cells owing to the use of optimal antimyeloma therapy which is based on the risk stratification. Disclosures Martynkevich: Pfizer: Honoraria, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau. Shuvaev:Novartis: Honoraria, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "006.350 72"

García González, Juan. "Civil War on Foreign Shores: M. Marius and the Roman Exiles in Asia Minor (75–72 BCE)." In Connected Histories of the Roman Civil Wars (88–30 BCE), 213–44. De Gruyter, 2024. http://dx.doi.org/10.1515/9783111431772-008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

"through tubing and fittings made of PTFE. Analysis was undertaken by the Warren Spring Laboratory of the Department of Trade and Industry, according to the method described by Bailey and Bedbo rough The results are shown in Table IV. and plotted in Fig. 3. and 4. Table IV. Variation of odour strength of extracted samples with volune of eluted air Volume of air Strength of odour samples passing through (dilutions) sludge before sampling (1/1) Raw sludge Digested sludge 0 154 000 9 900 11.1 53 000 350 22.2 30 600 270 55.6 15 500 190 111 8 200 160 It is clear from these results that there is considerable die-off of odour strength with time, and that, as would be expected, the anaerobic digestion of sludge can reduce the odour potential by at least one order of magnitude. To illustrate the importance of this die-off effect, the results have been re-plotted in Fig. 5. in a cunulative form; that is to say as cumulative percentage of the eventual colour release against volume of air. In the case of the raw sewage sludge, 38% of the ultimate odour was carried in the first odour sample, and 90% of the odour had been extracted by the passage of about 200 1. In the case of the anaerobically digested sludge, the same effect is much more marked; 72% of the ultimate odour was carried by the first sample, and thereafter the strength of the odour fell off very rapidly. There are two possible explanations for this. First, it can be postulated that as it is known that many of the important odorous chemical species are highly volatile, they may be only physically trapped in the sludge, and need little encouragement to transfer to the atmosphere. An alternative explanation concerns the existence of two equilibria. As the vapour/liquid equilibrium is disturbed by the passage of air, the concentration of dissolved compounds in the liquid phase falls, disturbing the ’solid’/liquid equilibrium The kinetics of transfer across this latter phase boundary are much slower than for the liquid/vapour transfer, so that the extraction of odour becomes limited by the rate of diffusion into the liquid phase. Two observations may be cited as evidence for this latter view. First, when sludge is applied to land, there is a rapid tail-off of odour nuisance after spreading. Hie incidence of rain after a dry period is known to result in an increased evolution of odour. Second, in earlier experiments samples of sludge were centrifuged, and the supernatant liquor discarded and replaced by tap water, before being used in the standard odour potential test. Some re-extraction of odour from the samples was rapidly found. In practice, both postulated mechanisms are probably at work, especially if the concept of ’solid/liquid equilibrium’ be extended to." In Odour Prevention and Control of Organic Sludge and Livestock Farming, 152. CRC Press, 1986. http://dx.doi.org/10.1201/9781482286311-64.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "006.350 72"

Pérez-Sánchez, A., V. Ruíz-Torres, L. Agulló-Chazarra, M. Herranz-Lopez, V. Micol, and E. Barrajón-Catalán. "PO-026 72 Rosemary (rosmarinus officinalis, L.) extract inhibits cell proliferation and migration in colon cancer cells lines." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.71.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Mayo, Michael, Jonathan Carroll, Nicholas Motahari, Warren Lee, and Robert Englar. "Wind Tunnel Test of a Blended Wing Aircraft in Ground Effect With Active Flow Control." In ASME 2016 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/imece2016-65683.

Повний текст джерела

Анотація:

This paper describes the test methodology and results for a wind tunnel experiment featuring a blended wing aircraft in ground effect with built-in circulation control. A 82.55cm wingspan blended wing model was tested in a subsonic wind tunnel at velocities ranging from 18m/s – 49m/s and corresponding Reynolds numbers ranging from 130k – 350k. Pitch angle was held constant at 0 degrees and the height above the wind tunnel floor was modified to determine lift and drag modification due to ground effect. At a normalized height (y/bw) of 0.06, ground effect increased lift production by 24% and reduced drag by 22% when compared to a normalized height of 0.5. The addition of the circulation control significantly increased the lift production of the model at a cost of increased drag. At a normalized height of 0.031, the lift production increased by 200% at a blowing coefficient of 0.01, but the drag also increased by 72%, ultimately increasing L/D by 178%. Experimental results also suggest that ground effect and circulation control have a synergistic effect when used simultaneously. The effects of Reynolds number and circulation control slot height are also investigated.

Стилі APA, Harvard, Vancouver, ISO та ін.

Chien, Liang-Han, Han-Yang Liu, and Wun-Rong Liao. "An Experimental Study of Two Phase Flow in Impinging Micro Channels." In ASME 2013 11th International Conference on Nanochannels, Microchannels, and Minichannels. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/icnmm2013-73073.

Повний текст джерела

Анотація:

A heat sink integrating micro-channels with multiple jets was designed to achieve better heat transfer performance for chip cooling. Dielectric fluid FC-72 was the working fluid. The heat sink contained 11 micro-channels, and each channel was 0.8 mm high, 0.6 mm wide, and 12 mm in length. There were 3 or 5 pores on each micro-channel. The pore diameters were either 0.24 or 0.4 mm, and the pore spacing ranged from 1.5 to 3 mm. In the tests, the saturation temperature of cooling device was set at 30 and 50°C, and the volume flow rate ranged from 9.1 to 73.6 ml/min per channel (total flow rate = 100∼810 ml/min). The experimental result showed that heat transfer performance increased with increasing flow rate for single phase heat transfer. For heat flux between 20 and 100 kW/m2, the wall superheat decreases with increasing flow rate at a fixed heat flux. However, the influence of the flow rate diminished when the channels are in two phase heat transfer regime. Except for the lowest flow rate (9.1 ml/min), the heat transfer performance increased with increasing jet diameter/spacing ratios. The best surface had three nozzles of 0.4 mm diameter in 3.0 mm jet spacing. It had the lowest thermal resistance of 0.0611 K / W in the range of 200 ∼ 240 W heat input.

Стилі APA, Harvard, Vancouver, ISO та ін.

Giannessi, D., R. De Caterina, G. Lazzerini, R. Sicari, and P. Gazzetti. "RELATIVE SENSITIVITY OF CARDIAC PROSTACYCLIN AND THROMBOXANE TO INHIBITION BY NON-STEROIDAL ANTIINFLAMMATORY DRUGS IN THE RAT HEART." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643390.

Повний текст джерела

Анотація:

We have previously shown that the isolated perfused rat Langendorff heart is able to synthesize detectable amounts of thromboxane (TX) A2, as well as prostacyclin (PGI2). Eicosanoid production in this system is increased during post-ischemic reperfusion, reflecting greater availability of substrate and net increase of synthesis. We assessed relative sensitivity of cyclooxygenases synthesizing TX and prostacyclin (probably located in different cell types) to aspirin (0.1, 0.5, 1 g/1), ibuprofen (1, 10, 80, 160, 320 mg/1) and diclofenac (0.01, 0.1, 0.5, 2.5, 5, 10, 25 mg/1), by radioimmunoassays of TXB2 and 6-keto-PGFα in the perfusate. Sixty Wistar male rat hearts were perfused with buffer containing control vehicle or drugs for 30 min, followed by 5 min clamping of the perfusion line and subsequent post-ischemic reperfusion. Baseline production was (mean±SD, pg/min/g wet weight) 754±261 and 143±66 for PGI2 and TXA2, respectively. Peak post-ischemic production was 7628±2673 and 1036±135, respectively. At doses of aspirin, ibuprofen and diclofenac (100, 10 and 2.5 mg/1, respectively) which were equally effective on prostacyclin production (mean % inhibition: 68, 67 and 72 for basal production and 90, 86 and 85 for peak post-ischemic production, respectively), % inhibition of TX production was consistently less, but also similar for the three drugs: 55, 58 and 56 for basal production and 78, 81 and 76 for peak post-ischemic production, for aspirin, ibuprofen and diclofenac, respectively; difference between inhibition of prostacyclin and TX: P < .01, difference for subsets among different drugs: N.S.). TX production was, on the contrary, selectively inhibited by the TX-synthase inhibitor 0KY 046 (by 79 and 92% at 0.1 mg/1, versus a complete sparing of prostacyclin production). The lesser sensitivity of cardiac (vascular?) TX versus prostacyclin to non-steroidal antiinflammatory drugs (NSAIDs) inhibition and the similar degree of inhibition by various NSAIDs, differing in structure and diffusing capacity, suggest heterogeneity among cyclooxygenases present in the system and different intrinsic sensitivity of TX- from prostacyclin-producing cyclooxygenases.

Стилі APA, Harvard, Vancouver, ISO та ін.

Wang, Ting, and Henry A. Long. "Performance and Economic Analysis of Biomass/Coal Co-Gasification IGCC Systems With Supercritical Steam Bottom Cycle: Part 1 — Post-Combustion Carbon Capture." In ASME 2012 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/imece2012-88430.

Повний текст джерела

Анотація:

In recent years, Integrated Gasification Combined Cycle (IGCC) technology has been gaining steady popularity for use in clean coal power operations with Carbon Capture and Sequestration (CCS). This study focuses on investigating two approaches to improve efficiency and further reduce the greenhouse gas (GHG) emissions. First, replace the traditional subcritical Rankine steam cycle portion of the overall plant with a supercritical steam cycle. Second, add different amounts of biomass as feedstock to reduce emissions. Part 1 focuses on investigating post-combustion CCS and Part 2 on analyzing pre-combustion CCS, using both sour-shift and sweet-shift processes. Employing biomass as a feedstock has the advantage of being carbon neutral or even carbon negative if CCS is implemented. However, due to limited feedstock supply, such plants are usually small (2–50MW), which results in lower efficiency and higher capital and production costs. Considering these challenges, it is more economically attractive and less technically challenging to co-combust or co-gasify biomass wastes with coal. Using the commercial software, Thermoflow®, this study analyzes the baseline plants around 235MW and 267 MW for the subcritical and supercritical designs, respectively. The results clearly show that utilizing a certain type of biomass with low-grade coals up to 50% (wt.) can, in most cases, not only improve the efficiency and reduce overall emissions, but may be economically advantageous, as well. The CO2 emissions decrease by about 7,000 tons/MW-year, making both plants carbon-negative with only 10% biomass in the feedstock. In addition, implementing a supercritical steam cycle raises the efficiency (1.6 percentage points) and lowers the capital costs ($300/kW), regardless of plant layout. Implementing post-combustion CCS consistently causes a drop in efficiency (at least 7–8 points) from the baseline, and increases the costs by $3,000-$4,000/kW and $0.06-$0.07/kW-hr. The SOx emissions also decrease by about 190 tons/year (7.6 × 10−6 tons/MW-year), while the NOx emissions are all but eliminated through post-combustion CCS. Finally, the CCS cost is around $65-$72 per ton of CO2.

Стилі APA, Harvard, Vancouver, ISO та ін.

Carneiro Filho, Genilson Gomes, Flávia Maria de Souza Climaco, Afranio Coelho-Oliveira, Bianca Kurtz Fontoura, Maria Celia Resende Djahjah, and Ana Helena Correia Carneiro. "Carcinoma primário em mama acessória axilar: relato de caso." In 44° Congresso da SGORJ - XXIII Trocando Ideias. Zeppelini Editorial e Comunicação, 2020. http://dx.doi.org/10.5327/jbg-0368-1416-2020130231.

Повний текст джерела

Анотація:

Introdução: A incidência de polimastia na população varia de 0,4 a 6,0%. O tecido glandular ectópico pode ser acometido por patologias benignas ou malignas. Entretanto, o carcinoma das mamas acessórias é raro, representando cerca de 0,3 a 0,6% de todos os cânceres de mama. Objetivo: Relatar um caso de carcinoma em mama acessória axilar, discutindo as características clínico-patológicas, as dificuldades do diagnóstico e as controvérsias em relação ao tratamento, em razão de sua raridade. Relato de Caso: Paciente de 61 anos, branca, apresenta queixa de nódulo em região axilar há um mês, com dor à palpação. Refere hipertensão arterial e hipotireoidismo. Menarca aos 12 anos. IIIG IIP IA. Amamentou por dez meses. Menopausa aos 52 anos. Nega reposição hormonal. Nega história familiar de neoplasias. Ao exame, apresenta mamas simétricas, flácidas e indolores. Ausência de retrações, abaulamentos ou nodulações. Presença de tecido glandular ectópico em região axilar direita, com nódulo de consistência endurecida, não aderido a planos profundos, medindo 2,0×3,0 cm, com lesão ulcerada não exsudativa. A mamografia demonstrou padrão de lipossubstituição, sem sinal de doença. BI-RADS I. A ultrassonografia detectou lesão nodular de alta densidade com limites imprecisos, espiculada, em mama acessória na região axilar direita. Mamas tópicas sem alterações. BI-RADS V. Realizada core biópsia com laudo de adenocarcinoma pouco diferenciado com padrão de crescimento difuso ou em fileiras, podendo corresponder a carcinoma lobular infiltrante ou a ductal infiltante ou ductal infiltrante com características lobulares. Imuno-histoquímica: CK7 positivo, CK20 negativo, antígeno carcinoembriônico positivo, RE positivo (90%), RP positivo (80%), KI67 positivo (50%), TTF-1 negativo, CERB B-2 negativo, E-CADERINA negativa. Indicada ressecção de mama acessória axilar e biópsia de linfonodo sentinela, sendo realizada injeção peritumoral de azul patente. O laudo histopatológico demonstrou carcinoma ductal infiltrante pouco diferenciado grau 3, com características lobulares, margens livres de neoplasia. Presença de metástase em um de dois linfonodos examinados. Realizada radioterapia adjuvante, quimioterapia e uso de anastrozol. Paciente permanece em acompanhamento, sem evidência de doença. Discussão: O carcinoma em mama acessória é raro e em 80% dos casos localiza-se na região axilar. O tipo histológico mais frequente é o carcinoma invasivo do tipo não especial (72%), seguido do lobular infiltrante. O diagnóstico, muitas vezes, é tardio, já que a mamografia pode não abordar adequadamente o tecido glandular. Incidências adicionais como a oblíqua e a craniocaudal forçada, assim como a ultrassonografia, permitem maior visualização do tecido ectópico. A ressecção da mama acessória com margens livres é o tratamento cirúrgico indicado. Não é necessária mastectomia, uma vez que a mama homolateral não está comprometida. A biópsia do linfonodo sentinela é uma alternativa viável na ausência de comprometimento ganglionar.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!